CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 3,357 enrolled
Drug / intervention
Use of blood pressure lowering medication at bedtime +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02990663
NCT02990663Phase 4Completed

The Effect of Antihypertensive Medication Timing on Morbidity and Mortality: The "BedMed" RCT

University of Alberta·interventional·Posted Dec 13, 2016·Updated Aug 27, 2024

In Brief

A Phase 4 clinical trial evaluating Use of blood pressure lowering medication at bedtime and Use of blood pressure lowering medication in the morning for Hypertension. Completed, enrolled 3,357 participants across 5 sites.

Detailed Summary

High blood pressure is common and its presence increases the risk of cardiovascular mortality and morbidity (most notably stroke, myocardial infarction, and congestive heart failure). Given blood pressure is normally higher during the day than it is overnight, blood pressure lowering medications are traditionally taken in the morning. However a randomized trial of 2156 Spanish hypertension patients published in 2010 ("MAPEC"), suggests a large (61%) reduction in mortality and cardiovascular morbidity if such medications are instead taken at bedtime. This degree of benefit far exceeds other established methods of cardiovascular risk reduction - and such a surprisingly large effect requires independent confirmation for practice to change. BedMed is a pragmatic randomized controlled trial facilitated by over 400 Canadian family physician members of the Pragmatic Trials Collaborative. During the conduct of this trial consenting hypertensive primary care patients, already established on one or more antihypertensive medications, will be randomized to either morning or bedtime antihypertensive use. Patient oriented trial outcomes evaluating both potential benefits and harms will be drawn largely from administrative health data that is routinely collected on all residents of Canada's publicly funded health care system. This trial is being conducted in 5 Canadian provinces and will continue to collect data until late 2023, at which point more than 255 primary outcome events are anticipated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesCanada

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 13, 2016
Enrollment StartMar 31, 2017
Primary CompletionDec 22, 2023
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 9.6 years ago

Interventions

Use of blood pressure lowering medication at bedtimeother

Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.

Use of blood pressure lowering medication in the morningother

Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.